Get to know our clinical trials
Multicenter, randomized, placebo-controlled, double-masked, multicenter phase III clinical trial of quemliclustat and chemotherapy compared to placebo and chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma.
THE AIM OF THIS STUDY IS TO DETERMINE WHETHER THE STUDY DRUGS, QUEMLICLUSTAT (ALSO KNOWN AS AB680) IN COMBINATION WITH GEMCITABINE AND NAB-PACLITAXEL CHEMOTHERAPY (GEM-NP), COMPARED TO A PLACEBO (SALINE SOLUTION CONTAINING NO ACTIVE INGREDIENTS) IN COMBINATION WITH GEMCITABINE AND NAB-PACLITAXEL CHEMOTHERAPY, WOULD BE SAFE AND EFFECTIVE IN TREATING PATIENTS WITH THE TYPE OF CANCER THEY HAVE.
Technical Summary
- MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-MASKED, MULTICENTER PHASE III CLINICAL TRIAL OF QUEMLICLUSTAT AND CHEMOTHERAPY COMPARED TO PLACEBO AND CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA.
- Code EudraCT: 2024-513317-12-00
- Protocol number: PRISM-1
- Promoter: Arcus Biosciencies
- Molecule/Drug: Quemliclustat (AB680)
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.